Taysha reports Q4 net loss $55.7M; cash $87.9M; progress on Rett and GAN trials

Taysha Gene Therapies, Inc.

Net loss Q4 2022: $55.7M ($0.99/shr) vs $50.4M Q4 2021; full year loss $166.0M vs $174.5M.
Cash $87.9M at 12/31/22; expected to fund operations into Q1 2024.
TSHA-102: screening started for REVEAL trial; first adult dosing H1 2023; initial safety data expected H1 2023.
TSHA-120: FDA suggests alternative trial designs; formal meeting request planned Q2 2023.
Non-cash impairment charge of $36.4M in Q4 2022 for NC manufacturing facility.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Taysha Gene Therapies, Inc. reported financial results for the fourth quarter and full-year ended December 31, 2022.

Period: the fourth quarter and full-year ended December 31, 2022
Result: reported results

Exact text from the filing

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today reported financial results for the fourth quarter and full-year ended December 31, 2022, and provided a corporate update.

View on SEC.gov

Browse all earnings releases →

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-082174

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.